Last €0.11 EUR
Change Today +0.001 / 0.89%
Volume 30.5K
DNR On Other Exchanges
As of 11:36 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

dendreon corp (DNR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/13 - €2.54
52 Week Low
11/17/14 - €0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DENDREON CORP (DNR)

dendreon corp (DNR) Related Businessweek News

No Related Businessweek News Found

dendreon corp (DNR) Details

Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington. On November 10, 2014, Dendreon Corp. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

710 Employees
Last Reported Date: 11/10/14
Founded in 1992

dendreon corp (DNR) Top Compensated Officers

Interim Chief Financial Officer, Principal Ac...
Total Annual Compensation: $354.1K
Compensation as of Fiscal Year 2013.

dendreon corp (DNR) Key Developments

Dendreon Receives Staff Delisting Determination Letter From The Listing Qualifications Staff Of Nasdaq

On November 10, 2014, Dendreon Corporation (the “Company”) and its wholly owned subsidiaries, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. On November 10, 2014, the Company received a Staff Delisting Determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1 (the “Listing Rules”), the Staff has determined that the Company’s securities will be delisted from Nasdaq unless the Company requests an appeal of such determination. The Listing Rules allow Nasdaq to use its discretionary authority to suspend or terminate the listing of a company based on any event, condition or circumstance that exists or occurs that makes continued listing of the securities on Nasdaq unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for continued listing on Nasdaq, including when a company has filed for protection under any provision of the federal bankruptcy laws. Nasdaq based its determination on the following factors: (i) the Chapter 11 Filings and associated public interest concerns raised by the Chapter 11 Filings; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. The letter provides that, should the Company fail to request a hearing before the Nasdaq Hearings Panel by November 17, 2014, trading of the Company’s securities will be suspended at the opening of business on November 19, 2014, and a Form 25-NSE will be filed with the Securities and Exchange Commission thereafter, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not anticipate requesting such a hearing, and thus expects that the Company’s securities will be delisted from Nasdaq.

Dendreon Corp. to Report Q3, 2014 Results on Nov 11, 2014

Dendreon Corp. announced that they will report Q3, 2014 results on Nov 11, 2014

Dendreon Corp. Looks For A Buyer

Dendreon Corp. (NasdaqGS:DNDN) will try to find a buyer through a bidding process and that it will continue as a stand-along business if no qualified bids are received. Dendreon has filed a motion with the Bankruptcy Court requesting that the court approve a bid deadline and set a date for an auction to implement the competitive process. In order for a bid received during the competitive process to be considered a qualified bid, it must have a value in excess of $275 million and meet certain other criteria, each as specified in the bidding procedures. The deadli9ne for bids is January 27, 2015 and the auction will be held on February 3, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNR:GR €0.11 EUR +0.001

DNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DNR.
View Industry Companies

Industry Analysis


Industry Average

Valuation DNR Industry Range
No financial data is available for DNR.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at